Jacobs Selected for Pfizer Swedish Biotech Project.PEAPACK, N.J. -- Jacobs Engineering Group Jacobs Engineering Group Inc. (NYSE: JEC), a publicly traded company with annual revenues approaching $7 billion, provides professional technical services. Headquartered in Pasadena, CA, Jacobs offers support to industrial, commercial, and government clients across multiple Inc. (NYSE NYSE See: New York Stock Exchange :JEC) announced today that they have been selected to develop a concept and preliminary design for a new biotech pharmaceutical facility for Pfizer, Inc., at Pfizer's Strangnas Manufacturing Center in Sweden. Officials did not disclose the contract value. The new facility enables Pfizer to ensure manufacturing capacity for existing biotech-derived pharmaceutical products. Jacobs is designing the manufacturing facility in accordance with current Good Manufacturing Practices Good Manufacturing Practice or GMP (also referred to as 'cGMP' or 'current Good Manufacturing Practice') is a term that is recognized worldwide for the control and management of manufacturing and quality control testing of foods and pharmaceutical products. (cGMP), Pfizer quality standards, and U.S. Food and Drug Administration and the European Medicines Agency The European Medicines Agency (EMEA) is a European agency for the evaluation of medicinal products. Until 2004, the European Medicines Agency was known as The European Agency for the Evaluation of Medicinal Products. Roughly parallel to the U.S. licensing requirements for bulk API (active pharmaceutical ingredient) production. Jacobs is executing the work from their office in Reading, England. Pfizer currently ranks as the world's largest manufacturer of pharmaceuticals and is committed to improving the quality of life for millions of people on a global basis. In making the announcement, Jacobs Group Vice President Phil Stassi stated, "We are excited to become part of Pfizer's biotech initiative. This award combines the product technology strengths of Pfizer with the global biotech project delivery expertise of Jacobs as we work together in support of Pfizer's commitment to provide life enhancing pharmaceuticals." Jacobs, with over 35,000 employees and revenues exceeding $5.0 billion, provides technical, professional, and construction services globally. Any statements made in this release that are not based on historical fact are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . Any forward-looking statements made in this release represent management's best judgement as to what may occur in the future. However, Jacobs' actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions ("Future Factors"), and may differ materially from what is expressed. For a description of Future Factors that could cause actual results to differ materially from such forward-looking statements, see the discussion under the section "Forward-Looking Statements" included in Item 7 -- Management's Discussion and Analysis Management's discussion and analysis (MD&A) A report from management to shareholders that accompanies the firm's financial statements in the annual report. It explains the period's financial results and enables management to discuss topics that may not be apparent in the financial of Financial Condition and Results of Operations contained in the Company's 2004 Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. . |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion